title: Fibrinolysis-inhibitory capacity of clot-embedded surfactant is enhanced by SP-B and SP-C.
abstract: Incorporation of pulmonary surfactant into fibrin inhibits its plasmic degradation. In the present study we investigated the influence of surfactant proteins (SP)-A, SP-B, and SP-C on the fibrinolysis-inhibitory capacity of surfactant phospholipids. Plasmin-induced fibrinolysis was quantified by means of a (125)I-fibrin plate assay, and surfactant incorporation into polymerizing fibrin was analyzed by measuring the incorporation of (3)H-labeled L-alpha-dipalmitoylphosphatidylcholine into the insoluble clot material. Incorporation of a calf lung surfactant extract (Alveofact) and an organic extract of natural rabbit large surfactant aggregates (LSA) into a fibrin clot revealed a stronger inhibitory effect on plasmic cleavage of this clot than a synthetic phospholipid mixture (PLX) and unprocessed LSA. Reconstitution of PLX with SP-B and SP-C increased, whereas reconstitution with SP-A decreased, the fibrinolysis-inhibitory capacity of the phospholipids. The SP-B effect was paralleled by an increased incorporation of phospholipids into fibrin. We conclude that the inhibitory effect of surfactant incorporation into polymerizing fibrin on its susceptibility to plasmic cleavage is enhanced by SP-B and SP-C but reduced by SP-A. In the case of SP-B, increased phospholipid incorporation may underlie this finding.
authors.affiliation: Department of Internal Medicine, Justus-Liebig-University-Giessen, Klinikstrasse 36, D-35385 Giessen, Germany.
authors.forename: Philipp
authors.initials: P
authors.lastname: Markart
authors.forename: Clemens
authors.initials: C
authors.lastname: Ruppert
authors.forename: Friedrich
authors.initials: F
authors.lastname: Grimminger
authors.forename: Werner
authors.initials: W
authors.lastname: Seeger
authors.forename: Andreas
authors.initials: A
authors.lastname: Günther
mesh_terms: D000818:Animals; D001777:Blood Coagulation / Q000502:physiology*; D002417:Cattle; D004338:Drug Combinations; D005337:Fibrin / Q000378:metabolism; D005342:Fibrinolysis / Q000187:drug effects / Q000502:physiology*; D008055:Lipids / Q000494:pharmacology; D010743:Phospholipids / Q000378:metabolism / Q000494:pharmacology; D037701:Pulmonary Surfactant-Associated Protein B / Q000494:pharmacology / Q000502:physiology*; D037721:Pulmonary Surfactant-Associated Protein C / Q000494:pharmacology / Q000502:physiology*; D011663:Pulmonary Surfactants / Q000378:metabolism* / Q000494:pharmacology; D011817:Rabbits
chemical_list: D004338:Drug Combinations; D008055:Lipids; D010743:Phospholipids; D037701:Pulmonary Surfactant-Associated Protein B; D037721:Pulmonary Surfactant-Associated Protein C; D011663:Pulmonary Surfactants; C078272:SF-RI 1, bovine surfactant preparation; D005337:Fibrin